# Campfield Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/campfield-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.campfieldtx.com
- Total disclosed funding: $180M
- Latest round: Series A (Jun 19, 2026)
- Investors on record: 8

## About

Founded in 2026 and headquartered in San Diego, US, Campfield is cofounded by David Socks(COO). Campfield Therapeutics specializes in innovative therapeutic solutions for inflammatory diseases. The company was established to develop its flagship product, Prifemilast, as part of its initial business strategy. The firm has completed one funding round, raising USD 180.00 mn in Series A financing on June 19, 2026, led by Frazier Life Sciences, with participation from Abingworth, Deep Track Capital, Forbion, Longitude Capital, Novo Holdings, RA Capital Management, and Venrock. AS of July 2026, Campfield is led by Bill Gerhart as a CEO and Patricia Turney as CTO
Campfield Therapeutics specializes in the development of innovative oral medicines targeted at the treatment of immune-mediated inflammatory diseases, with a primary focus on inflammatory bowel disease (IBD). Their flagship product, Prifemilast, is a once-daily oral PDE4B-selective inhibitor designed to enhance cAMP signaling in immune cells, thereby reducing inflammation associated with conditions such as ulcerative colitis and Crohn's disease. This investigational therapy has demonstrated robust efficacy and a favorable tolerability profile in over 700 clinical trial participants, including notable results from a Phase 3 trial in plaque psoriasis. The company aims to address significant unmet needs in the IBD treatment landscape by offering a more convenient and effective therapeutic option compared to currently available treatments, which are often limited by poor tolerability and safety concerns. Prifemilast is being developed for global markets, with clinical trials currently underway in North America and other international regions.
Campfield Therapeutics has recently launched with USD 180.00 mn in Series A financing, aimed at advancing Prifemilast into global Phase 2 trials for moderate-to-severe ulcerative colitis and Crohn's disease. Revenue generation is anticipated through partnerships and collaborations, particularly with biopharmaceutical firms such as Newsoara Biopharma, which is developing Prifemilast for the Greater China market. The company’s business model includes B2B partnerships with healthcare providers and institutions, focusing on the distribution of their oral therapies to patients requiring effective IBD treatments. While precise pricing plans have not been disclosed, transactions will primarily occur through negotiated agreements with healthcare systems and possibly insurance providers.
In June 2026, Campfield Therapeutics, Inc. raised USD 180.00 mn in Series A funding, which will be utilized to advance prifemilast (HY1999/HPP737), a once-daily oral PDE4 inhibitor for IBD. The company plans to expand its clinical trials for Prifemilast into additional global markets, with a focus on North America and other regions as trials progress. This strategic funding will support further research and development efforts, aiming to enhance the accessibility of their innovative treatments in new geographical areas.

## Funding rounds

- Series A, Jun 19, 2026, $180M — Abingworth, Venrock, Novo Holdings, Forbion, Longitude Capital, RA Capital Management, Deep Track Capital, Frazier Life Sciences

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- Novo Holdings — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series A
- Frazier Life Sciences — Series A